



HAL
open science

The ambiguous role of FPR1 in immunity and inflammation

Erika Vacchelli, Julie Le Naour, Guido Kroemer

► **To cite this version:**

Erika Vacchelli, Julie Le Naour, Guido Kroemer. The ambiguous role of FPR1 in immunity and inflammation. *OncoImmunology*, 2020, 9 (1), pp.e1760061. <10.1080/2162402X.2020.1760061>. <hal-04702736>

HAL Id: hal-04702736

<https://hal.science/hal-04702736v1>

Submitted on 19 Sep 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

The ambiguous role of FPR1 in immunity and inflammation

Erika Vacchelli^{a,b,c}, Julie Le Naour^{a,b,c,d}, and Guido Kroemer^{a,b,c,e,f,g}

^aEquipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Centre de Recherche des Cordeliers, Paris, France; ^bMetabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France; ^cGustave Roussy Cancer Campus, Villejuif, France; ^dUniversité Paris Sud, Paris Saclay, Faculty of Medicine Kremlin Bicêtre, Paris, France; ^eHôpital Européen Georges Pompidou, AP-HP, Paris, France; ^fSuzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China; ^gKarolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden

ARTICLE HISTORY Received 14 April 2020; Revised 21 April 2020; Accepted 21 April 2020

Formyl peptide receptors (FPRs) are pattern recognition receptors (PPRs) that are involved in multiple pathological processes. These G protein-coupled receptors expressed by immune cells transduce chemotactic signals to trigger cell adhesion, migration, generation of reactive oxygen species (ROS) as well as tissue repair and angiogenesis.¹

Among the three FPRs known in humans (FPR1, FPR2 and FPR3), most studies have focused on FPR1.² Their main ligands, N-formylated peptides, are either produced by invading bacteria or released from degrading mitochondrial proteins contained in dying host cells.¹ Although FPRs are expressed in various immune cells^{1,3} among which neutrophils, macrophages, natural killer and dendritic cells, studies on FPR1 functions mostly focus on neutrophils, which often are the leukocytes to migrate toward the site of inflammation.²

FPR1 has an ambivalent role in pathogenic processes (Figure 1). In some diseases, FPR1 has a positive effect. In the context of infection by *Escherichia coli*⁴ and *Listeria monocytogenes*,⁵ a genetic FPR1 deficiency (genotype: *Fpr1*^{-/-}) compromises pathogen elimination in mice, therefore, increasing mortality. Indeed, in the context of bacterial infection, FPRs induce trafficking of phagocytes to the site of microbial invasion and increase the phagocytic destruction of the pathogens.⁶ In cancers developing on *Fpr1*^{-/-} mice, the recruitment and positioning of dendritic cells into the tumor bed (and not that of neutrophils as in many other scenarios) is reduced in response to chemotherapy, thereby compromising the antitumor immune response required for chemotherapy to be efficient.^{7,8} FPR1 has several endogenous ligands including Annexin A1 (ANXA1), cathepsin G (CTSG), family with sequence similarity 19 (chemokine (C-C motif)-like) member A4 (FAM19A4) and N-formylated peptides contained in mitochondria. *In vivo* experiments revealed that only the deletion of the gene coding for *Annexin A1* (ANXA1) compromised the capacity of dying cancer cells to induce anticancer immune responses.⁷ Thus, the cancer immunosurveillance-relevant ligand of FPR1 appears to be ANXA1.

In sharp contrast, in many other diseases, FPR1 has negative effects, meaning that its neutralization might be considered as a therapeutic intervention. For example, *Fpr1*^{-/-} mice are protected against infection by *Yersinia pestis*, in line with the discovery that FPR1 acts as the receptor for this pathogen,

which is the causative agent of human plague.⁹ Moreover, *Fpr1*^{-/-} mice subjected to ischemia-reperfusion damage to the heart present reduced inflammation, cardiomyocyte apoptosis and ventricular remodeling, accompanied by the inhibition of the mitogen-activated protein kinases (MAPK) pathway.¹⁰ Similarly, FPR1 plays a negative role in celiac disease, a highly prevalent autoimmune disorder that can be attenuated but not cured by a gluten-free diet. Indeed, FPR1 promotes the proinflammatory migration of neutrophils into the gut following exposure to gliadin (the pathogenic component of gluten).¹¹ Acute endotoxin-induced lung injury is also attenuated in *Fpr1*^{-/-} mice commensurate with reduced local neutrophil recruitment.¹² Similarly, *Fpr1*^{-/-} mice are protected from cigarette smoking-induced lung emphysema, coupled to a drastic reduction in the migration of neutrophils and macrophages to the lung after smoke exposure.¹³ Indeed, patients with chronic obstructive pulmonary disease exhibiting an increased expression of FPR1 on peripheral neutrophils and in bronchoalveolar fluids.¹³ Finally, *Fpr1*^{-/-} mice do not develop pulmonary fibrosis in response to intratracheal bleomycin challenge and failed to recruit neutrophils to the damaged lungs.² Adoptive transfer experiments allowed to conclude that the cell type that has to express FPR1 to cause bleomycin-induced lung fibrosis is neutrophils, underscoring the importance of this leukocyte subpopulation for disease pathogenesis.²

Of note, more than 200 single nucleotide polymorphisms (SNPs) have been described for FPR1, and this heterogeneity could influence the functional (positive or negative) role of the gene in various diseases. In some cases, such as aggressive periodontitis¹⁴ or exudative age-related macular degeneration and polypoidal choroidal vasculopathy¹⁵ a functional defect of the gene constitutes a potential risk factor. In the context of cancer, the loss-of-function variation rs867228 (G346A affecting the intracellular C-terminus of FPR1) is associated with reduced survival in breast and colorectal cancer patients treated by immunogenic chemotherapy.⁷ *FPR1* rs5030880 (R190 W affecting the extracellular loop 2 of FPR1) may constitute plague resistance allele. Indeed, monocytes from individuals bearing this polymorphism exhibit a reduced migration toward formylated peptides or *Y. pestis*.⁹




Figure 1. Positive and negative roles of FPR1 in disease pathogenesis.

Abbreviations: DC, dendritic cell; FPR1, formyl peptide receptor 1; I/R, ischemia/reperfusion; MAPK, mitogen-activated protein.

Given the ambiguity of FPR1 in the pathogenesis of disease (Figure 1), from a teleological point of view, it might be important to maintain a heterogeneity in the population that then would constitute an equilibrated mix of individuals some of which, for example, are resistant against some infectious agents (*Y. pestis* and endotoxin-induced lung damage in the case of a loss-of-function allele) at the cost of being more susceptible to other pathogens (*E. coli* and *L. monocytogenes*, for the loss-of-function allele) and *vice versa*. Indeed, rs5030880 occurs in ~12% of Caucasians as well as in ~9% of Africans and Afro-Americans and in ~18% of Asians. Similarly, a sizable fraction of the population (~30% of Caucasians) harbors the loss-of-function allele of rs867228. As an aside, such functionally relevant polymorphisms may impact anticancer immunosurveillance requiring functional dendritic cells⁷ as well as chronic inflammation mediated by FPR1 expressing macrophages³ and neutrophils.² It will be important to determine the impact of genetic polymorphisms affecting FPRs and other PRRs in more detail, in a systematic fashion, to understand their importance in the initiation and resolution of inflammatory and immune responses.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Abbreviations

ORCID

Guido Kroemer  <http://orcid.org/0000-0002-9334-4405>

References

- Dorward DA, Lucas CD, Chapman GB, Haslett C, Dhaliwal K, Rossi AG. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. *Am J Pathol.* 2015;185:1172–1184. doi:10.1016/j.ajpath.2015.01.020.
- Leslie J, Millar BJ, Del Carpio Pons A, Burgoyne RA, Frost JD, Barksby BS, Luli S, Scott J, Simpson AJ, Gaudie J, et al. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. *JCI Insight.* 2020;5(4). doi:10.1172/jci.insight.125937.
- Gemperle C, Schmid M, Herova M, Marti-Jaun J, Wuest SJ, Loretz C, Hersberger M. Regulation of the formyl peptide receptor 1 (FPR1) gene in primary human macrophages. *PLoS One.* 2012;7(11):e50195. doi:10.1371/journal.pone.0050195.
- Zhang M, Gao J-L, Chen K, Yoshimura T, Liang W, Gong W, Li X, Huang J, McDermott DH, Murphy PM. A critical role of formyl peptide receptors in host defense against *Escherichia coli*. *J Immunol.* 2020;ji1900430. doi:10.4049/jimmunol.1900430.
- Liu M, Chen K, Yoshimura T, Liu Y, Gong W, Wang A, Gao J-L, Murphy PM, Wang JM. Formylpeptide receptors are critical for rapid neutrophil mobilization in host defense against *Listeria monocytogenes*. *Sci Rep.* 2012;2(1):786. doi:10.1038/srep00786.
- Prevete N, Liotti F, Marone G, Melillo RM, de Paulis A. Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. *Pharmacol Res.* 2015;102:184–191. doi:10.1016/j.phrs.2015.09.017.
- Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietroccola F, Yang H, Adjemian S, Chaba K, Semeraro M. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. *Science.* 2015;350(6263):972–978. doi:10.1126/science.aad0779.
- Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Dermaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. *J Immunother Cancer.* 2020;8. pii: e000337. doi: 10.1136/jitc-2019-000337
- Osei-Owusu P, Charlton TM, Kim HK, Missiakas D, Schneewind O. FPR1 is the plague receptor on host immune cells. *Nature.* 2019;574:57–62. doi:10.1038/s41586-019-1570-z.
- Zhou QL, Teng F, Zhang YS, Sun Q, Cao YX, Meng GW. FPR1 gene silencing suppresses cardiomyocyte apoptosis and ventricular remodeling in rats with ischemia/reperfusion injury through the inhibition of MAPK signaling pathway. *Exp Cell Res.* 2018;370:506–518. doi:10.1016/j.yexcr.2018.07.016.
- Lammers KM, Chieppa M, Liu L, Liu S, Omatsu T, Janka-Junttila M, Casolaro V, Reinecker H-C, Parent CA, Fasano A, et al. Gliadin induces neutrophil migration via engagement of the formyl peptide receptor, FPR1. *PLoS One.* 2015;10(9):e0138338. doi:10.1371/journal.pone.0138338.
- Grommes J, Drechsler M, Soehnlein O. CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury. *J Innate Immun.* 2014;6:111–116. doi:10.1159/000353229.

13. Cardini S, Dalli J, Fineschi S, Perretti M, Lungarella G, Lucattelli M. Genetic ablation of the *fpr1* gene confers protection from smoking-induced lung emphysema in mice. *Am J Respir Cell Mol Biol.* 2012;47:332–339. doi:10.1165/rcmb.2012-0036OC.
14. Maney P, Emecen P, Mills JS, Walters JD. Neutrophil formylpeptide receptor single nucleotide polymorphism 348T>C in aggressive periodontitis. *J Periodontol.* 2009;80:492–498. doi:10.1902/jop.2009.080225.
15. Liang XY, Chen LJ, Ng TK, Tuo J, Gao JL, Tam PO, Lai TYY, Chan -C-C, Pang CP. FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy. *Eye (Lond).* 2014;28:1502–1510. doi:10.1038/eye.2014.226.